| Zeit | Aktuelle Nachrichten Sprache: 
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.10. | Aptamer hails year of "significant progress" as revenue rises 40% | 1 | Alliance News | ||
| 14.10. | Aptamer Group PLC - Full Year Results for the 12mths to 30 June 2025 | 1 | RNS | ||
| 13.10. | Aptamer wins contract with 'top 10' repeat customer | 1 | Sharecast | ||
| 13.10. | Aptamer Group PLC - New contract with top 10 pharma | - | RNS | ||
| 10.10. | Aptamer Group legt Jahresergebnisse am 14. Oktober vor | 2 | Investing.com Deutsch | ||
| 10.10. | Aptamer Group to announce full year results on Tuesday | 2 | Investing.com | ||
| 10.10. | Aptamer Group PLC - Notice of Results, Analyst & Investor Presentation | 3 | RNS | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 08.10. | Aptamer wins major pharmaceutical contract and grows order book | 3 | Alliance News | ||
| 08.10. | Aptamer Group PLC - Major top 3 global pharma contract win | 1 | RNS | ||
| 06.10. | AIM Market Roundup: HSS Hire, Aptamer, EQTEC | 18 | The Armchair Trader | ||
| 26.09. | Aptamer Group PLC - Investor Event and Presentation | 1 | RNS | ||
| 11.09. | Aptamer and Metir agree contract for detection of waterborne parasite | 4 | Alliance News | ||
| 11.09. | Aptamer Group signs development contract with Metir | 1 | Sharecast | ||
| 11.09. | Aptamer Group PLC - New contract with Metir plc | 1 | RNS | ||
| 11.09. | Metir PLC - New Contract with Aptamer Group | - | RNS | ||
| 09.09. | Director dealings: Aptamer chairman raises stake | 3 | Sharecast | ||
| 09.09. | Aptamer Group PLC - Notification of dealings by a director/PDMR | 1 | RNS | ||
| 03.09. | Aptamer Group Partners with Invizius to Develop Next-Gen Complement System Therapies | 3 | Contract Pharma | ||
| 02.09. | Aptamer Group PLC - Therapeutic development agreement with Invizius | 1 | RNS | ||
| 27.08. | Aptamer launches biomarker discovery service to expand revenue base | 1 | The Armchair Trader | 
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,760 | +0,90 % | QIAGEN N.V.: QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025 | New EZ2 DNA Investigator Sep&Prep Kit automates sexual assault sample processing, improving sperm DNA recovery and separation from victim DNA  		   Workflow on EZ2 Connect Fx delivers high-quality... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,84 | +0,23 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| EVOTEC | 7,054 | -0,59 % | BB Biotech & Evotec: Biotech immer noch historisch "billig"? Und die bessere Aktie ist? | BB Biotech & Evotec: Zwei Aktien, die ein klar unterschiedliches Risikopotential bieten. Deshalb die Frage: Wird höheres Risiko durch höhere Gewinnchncen ausgeglichen? Ein Aktienvergleich für Anleger... ► Artikel lesen | |
| BIONTECH | 89,65 | -0,83 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| RECURSION PHARMACEUTICALS | 5,460 | -3,02 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| MODERNA | 23,620 | -1,11 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CABALETTA BIO | 3,305 | +34,62 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| INHIBRX BIOSCIENCES | 78,80 | +0,44 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,630 | +3,55 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| INTENSITY THERAPEUTICS | 0,792 | -39,52 % | Intensity Therapeutics announces pricing of $4M registered direct offering of common stock | ||
| PHATHOM PHARMACEUTICALS | 13,260 | -1,04 % | Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth | ||
| VENTYX BIOSCIENCES | 8,920 | +6,00 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,446 | -23,76 % | Harvard Bioscience, Inc.: Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States | HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a leading provider of innovative laboratory equipment, is pleased... ► Artikel lesen | |
| IMMUNOVANT | 24,880 | +0,28 % | Immunovant gains amid takeover speculation | ||
| CUREVAC | 4,604 | 0,00 % | CureVac beruft außerordentliche Hauptversammlung für 25. November ein |